Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 53: 1835-1840, 2007. First published August 16, 2007; 10.1373/clinchem.2006.084947
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow 084947.Supplemental Data
Right arrow All Versions of this Article:
clinchem.2006.084947v1
53/10/1835    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lim, P.
Right arrow Articles by Guéret, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lim, P.
Right arrow Articles by Guéret, P.
Related Collections
Right arrow General Clinical Chemistry
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2007;53:1835-1840.)
© 2007 American Association for Clinical Chemistry, Inc.

General Clinical Chemistry

Fetuin-A Is an Independent Predictor of Death after ST-Elevation Myocardial Infarction

Pascal Lim1,a, Jean-Phillipe Collet2,2, Stéphane Moutereau3,2, Nathalie Guigui1, Laurens Mitchell-Heggs1, Sylvain Loric3, Magy Bernard4, Said Benhamed4, Gilles Montalescot2, Jean-Luc Dubois Randé1 and Pascal Guéret1

1 Department of Cardiology, Assistance Publique Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.
2 Department of Cardiology, Assistance Publique Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale 856, Pitie Salpetriere Hospital, Paris, France.
3 Biochemistry Laboratory, Assistance Publique Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France.
4 Biochemistry Laboratory, Assistance Publique Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale 856, Pitie Salpetriere Hospital, Paris, France.

aAddress correspondence to this author at: Henri Mondor Hospital, Department of Cardiology, 51 Av du Maréchal de Lattre de Tassigny, 94010 Créteil, France. Fax 33-1-49812801; e-mail lim.pascal.hmn{at}gmail.com.

Background: Fetuin-A inhibits inflammation and has a protective effect against myocardial ischemia. Its deficiency has been found to be associated with cardiovascular death in patients with end-stage renal failure disease. We investigated the association between plasma fetuin-A and clinical outcome after ST-elevation acute myocardial infarction (STEMI).

Methods: We measured fetuin-A in 284 consecutive patients with STEMI and correlated these data with the occurrence of death at 6 months (n = 25). We also measured fetuin-A in a control group and chose the 95th percentile as the cutoff to define abnormality.

Results: Patient mean (SD) age was 60 (14) years, and creatinine clearance was 83 (31) mL/min; 82% were men. Mean (SD) plasma fetuin-A concentrations at admission [188 (69) mg/L, P = 0.01] and at day 3 [163 (57) mg/L, P <0.0001] were lower in patients than in controls [219 (39) mg/L; 95th percentile 140 mg/L]. Fetuin-A <140 mg/L was observed in 20% of patients at admission vs 40% at day 3 (P <0.001). Fetuin-A concentrations did not correlate with peak cardiac troponin values but did correlate inversely with C-reactive protein (CRP) and NT-pro-brain natriuretic peptide (NT-proBNP). Fetuin-A <140 mg/L at admission (OR = 3.3, P = 0.03) and at day 3 (OR = 6.3, P = 0.002) was an independent correlate of death at 6 months, irrespective of NT-proBNP, CRP, or Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) risk score. Conversely, fetuin-A ≥140 mg/L was associated with an excellent survival rate [negative predictive value (NPV) = 97% overall], even in high-risk populations with CADILLAC risk score ≥6 (NPV = 90% in patients).

Conclusions: Fetuin-A is an important predictor of death at 6 months in STEMI patients independent of NT-proBNP, CRP, and CADILLAC risk score.




The following articles in journals at HighWire Press have cited this article:


Home page
 JAMAHome page
J. H. Ix, C. L. Wassel, A. M. Kanaya, E. Vittinghoff, K. C. Johnson, A. Koster, J. A. Cauley, T. B. Harris, S. R. Cummings, M. G. Shlipak, et al.
Fetuin-A and Incident Diabetes Mellitus in Older Persons
JAMA, July 9, 2008; 300(2): 182 - 188.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
R. C Shroff, V. Shah, M. P Hiorns, M. Schoppet, L. C Hofbauer, G. Hawa, L. J Schurgers, A. Singhal, I. Merryweather, P. Brogan, et al.
The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not Matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis
Nephrol. Dial. Transplant., May 9, 2008; (2008) gfn226v2.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Association for Clinical Chemistry.